In this final analysis of the phase 3 ATALANTE/ENGOT-ov29 trial, researchers evaluated 5-year OS outcomes with and without the addition of atezolizumab to standard care.

Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.

This study evaluates public awareness of the link between human papillomavirus (HPV) and cervical cancer and examines the various factors that influence this knowledge among adults in the United ...

The FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for pretreated, advanced squamous cell carcinoma of the anal canal based on phase 1/2 GOBLET trial ...

(HealthDay News) — Remote patient-reported outcome (PRO) monitoring may improve cancer care for underserved patients, according to a study recently published in JCO Oncology Practice.

For this nationally representative survey, researchers aimed to determine how many US workers feel locked into their jobs to maintain health insurance, as well as factors that contribute to this job ...

In this study, researchers aimed to compare the efficacy of zanidatamab-based combinations against the current standard of care in treatment-naïve, advanced, HER2+ gastric/GEJ cancer.

AYA cancer patients with sarcoma may not know resources, including palliative care, are available, and may resist them when ...

The preferred management of patients with recurrent platinum-sensitive ovarian cancer (PSOC) is platinum-based doublet therapy with selective ...

To examine the association between vitiligo and skin cancer, researchers compared individuals with a first recorded diagnosis of vitiligo with participants who had a general health care encounter that ...

Investigators pooled data from 4 trials to evaluate risk for recurrence in patients with intermediate risk non-muscle-invasive bladder cancer.

Investigators examined the effect of postpartum status on the 21-gene Oncotype DX Recurrence Score in women with hormone ...